• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Prelude Therapeutics

Parachute over La Jolla California
Biotech

Metsera sale architect swings to Structure—Chutes & Ladders

Metsera acquisition architect swings to Structure. Vir CMO exits after less than 2 years. Leal reels in Big Pharma vets to exec team.
Darren Incorvaia , Zoey Becker , Will Maddox Apr 17, 2026 10:10am
pipeline valve pipe flow water tap

Prelude loses CMO, pauses SMARCA2 degraders, scores Incyte cash

Nov 4, 2025 9:40am
sheet music wrong note

Prelude calls it curtains on lead SMARCA2 cancer asset

Aug 14, 2025 10:44am
pile of cash piggy bank money cash dollars bills spend

Pathos AI's $365M series D to fund trial of Novo tumor drug

May 15, 2025 10:20am
Photo of an ax atop a pile of three logs

Prelude thinks SMARCA with AbCellera deal, culls 2 candidates

Nov 2, 2023 8:06am
mountain top climb

3 more biotechs look to cull, partner assets

Nov 14, 2022 11:40am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings